Loading stock data…
$19.86+0.30 (+1.51%)
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
Amneal Pharmaceuticals, Inc. in the Healthcare sector is trading at $19.86 with a market capitalization of $6.3B. Wall Street consensus targets $22.71 (7 analysts), implying a +14.3% move over the next 12 months. The stock is currently near its 52-week high of $21.18, remaining 29.8% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $796.20M↑ | $722.52M↓ | $814.32M↑ | $784.51M↑ | $724.51M |
| Gross Profit | $334.51M↑ | $320.11M↑ | $297.19M↑ | $273.97M↓ | $286.25M |
| Operating Income | $145.98M↓ | $148.27M↑ | $114.50M↑ | $70.49M↓ | $112.01M |
| Net Income | $57.66M↓ | $62.26M↑ | $35.08M↑ | $2.37M↓ | $22.42M |
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internation...